【レポートの概要（一部）】
1. Report Overview
1.1 The Companion Diagnostics Market Overview
1.2 Companion Diagnostics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Introduction to Companion Diagnostics
2.1 The Foundation of Personalised Medicine
2.2 Personalised Medicine: Changing the Patient Treatment Paradigm
2.3 In Vitro Diagnostic (IVD) Tests
2.3.1 Companion Diagnostics: A Type of IVD
2.3.2 Differences between Companion Diagnostics and Theranostics
2.3.3 Biomarkers to Companion Diagnostics
2.3.4 Genomic Biomarkers
2.3.5 Genomic Oncology Biomarkers
2.4 Regulations in the Companion Diagnostics Market
2.4.1 FDA’s Final Guidance on Companion Diagnostics
2.4.2 LDTs: A Changing Landscape
2.5 Encouraging the Contemporaneous Development of Companion Diagnostics
3. The World Companion Diagnostics Market, 2016-2026
3.1 Scope and Limitations
3.2 The Global Companion Diagnostics Market, 2014 and 2015
3.3 The Global Companion Diagnostics Market Sales Forecast, 2016-2026
3.4 Companion Diagnostics: Growth Outpacing the Rest of the IVD Market
3.5 Companion Diagnostics: Increasing Market Share of the IVD Market
3.6 The Companion Diagnostics Market by Submarket, 2014
3.7 Theranostics: Fastest Growing Segment of the CDx Market
3.8 Changing Market Shares of the Leading Companion Diagnostics Submarkets, 2015-2025
4. Leading National Markets for Companion Diagnostics, 2016-2026
4.1 The Leading National Markets for Companion Diagnostics: Led by 3 Dominant Markets in 2014 & 2015
4.2 The Leading National Markets for Companion Diagnostics Sales Forecast, 2016-2026
4.2.1 Changing Market Shares of Leading National Markets, 2016-2026
4.3 The US Companion Diagnostics Market Sales Forecast, 2016-2026
4.3.1 The US Will Continue to Dominate the Market
4.4 The EU5 Companion Diagnostics Sales Market, 2014
4.4.1 The EU5 Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.2 Changing Market Shares of the EU5 Companion Diagnostics Market
4.4.3 The German Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.4 The French Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.5 The Italian Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.6 The Spanish Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.7 The UK Companion Diagnostics Market Sales Forecast, 2016-2026
4.5 The Japanese Companion Diagnostics Market Sales Forecast, 2016-2026
4.5.1 Japan’s Medical Technology Regulatory Process Reducing Time to Market
4.6 The Chinese Companion Diagnostics Market Sales Forecast, 2016-2026
4.6.1 Cancer Rates will Drive Adoption of Companion Diagnostic Tests
4.7 The Indian Companion Diagnostics Market Sales Forecast, 2016-2026
4.8 The Brazilian Companion Diagnostics Market Sales Forecast, 2016-2026
4.9 The Russian Companion Diagnostics Market Sales Forecast, 2016-2026
4.10 The South Korean Companion Diagnostics Market Sales Forecast, 2016-2026
4.11 The Rest of the World Companion Diagnostics Market Sales Forecast, 2016-2026
5. The Companion Diagnostics Market: Marketed Products and Pipeline Partnerships
5.1 Biomarkers: At the Forefront of Companion Diagnostics Development
5.2 US FDA Approved Companion Diagnostic Tests, 2016
5.3 Oncology Continues to Dominate the R&D Pipeline of Companion Diagnostics
5.4 Expensive Cancer Therapies Encourages the Development of CDx
5.5 Companion Diagnostic/Pharma Partnerships, 2013-2014
6. Business Models and Stakeholders in the Companion Diagnostics Market
6.1 Business Models for the Development of Companion Diagnostics
6.1.1 The Partnership Model is the Most Practiced Method
6.1.2 The Stand-Alone Model: Licensing an IP
6.1.3 The One Stop Shop Model: An Approach by Big Pharma
6.1.4 Using Contract Diagnostics Organisations (CDO): An Emerging Trend
6.2 Factors Driving Companies to Enter the Companion Diagnostics Market
6.3 Stakeholders Influencing the Companion Diagnostics Market
6.3.1 Pharmaceutical Companies and Diagnostic Manufacturers
6.3.2 Regulatory Authorities
6.3.3 Testing Laboratories
6.3.4 Physicians and Patients
6.3.5 Payers
6.4 Companion Diagnostics Competitive Landscape, 2016
7. Leading Companies in the Companion Diagnostics Market 2015
7.1 Roche: Global Diagnostics Leader
7.1.1 Ventana Medical Systems (Roche)
7.1.2 Sales and Recent Performance Analysis, 2014
7.1.3 Roche Diagnostics by Region, 2014
7.1.4 Roche: Internal Growth
7.1.5 Approval of Tarceva and Cobas EGFR Mutation Test
7.1.6 Roche’s Portfolio of Companion Diagnostic Project Pipeline and Marketed Companion Diagnostics, 2015
7.1.7 Ventana Companion Diagnostics: Robust New Prototype Assays
7.1.8 Recent Companion Diagnostic External Collaborations, 2014-2015
7.1.8.1 Ventana/Genmab
7.1.8.2 Ferring/ Roche: CDx Development for Infertility Treatment
7.1.8.3 MedImmune (AstraZeneca)/Ventana: Assay for NSCLC Targeted Clinical Trials
7.1.8.4 Merck/Ventana: CDx for an Undisclosed Target
7.1.8.5 AstraZeneca/Roche: CDx to Support Target Drug AZD9291
7.1.8.6 Boehringer Ingelheim/Roche
7.1.8.7 ImmunoGen/ Ventana
7.1.8.8 Foundation Medicine/Roche
7.1.9 Roche: Major M&A Activity and Strategic Partnerships Strengthen Position as Diagnostic Market Leader
7.1.9.1 Genia Acquisition to Strengthen DNA Sequencing Capabilities
7.1.9.2 IQuum Acquisition Allows Movement into POC MDx Market
7.1.9.3 Seragon Acquisition Strengthens Leading Position in Oncology
7.1.9.4 Santaris Acquisition Enchances Roche’s Position in RNA-Targeted Drugs Market
7.1.9.5 Bina Acquisition Brings Big Data Solution to Support NGS Development
7.1.9.6 Dutalys Acquisition Enhances Roche’s mAB Portfolio
7.1.9.7 Ariosa Acquisition Adds NIPT to Diagnostic Portfolio
7.1.9.8 Foundation Medicine Deal Enhances Personalised Medicine Capabilities for Oncology
7.1.9.9 Signature and CAPP Acquisitions Strengthen Circulating DNA Testing Abilities
7.1.9.10 GENEWEAVE and Kapa Acquisitions Help Cement Roche’s Position as the Market Leader
7.2 Qiagen N.V.: Leading CDx Collaborator with Pharmaceutical Companies
7.2.1 Sales and Recent Performance Analysis, 2010-2015
7.2.2 Qiagen Sales By Region
7.2.3 Companion Diagnostics Collaboration Agreements with Pharma, 2015
7.2.3.1 Collaboration with Eli Lilly
7.2.3.2 Collaboration with AstraZeneca
7.2.3.3 Collaboration with Astellas Pharma
7.2.3.4 Collaboration with Novartis
7.2.3.5 Collaboration with Array BioPharma
7.2.3.6 Collaboration with Protagen
7.3 Abbott Molecular: An Established Competitor
7.3.1 Sales and Recent Performance Analysis, 2012-2015
7.3.2 Abbott Molecular: Expansive Oncology Biomarker Pipeline
7.3.3 Recent Activity and Collaborations
7.3.3.1 Collaboration with Merck
7.3.3.2 Collaborative Efforts with Idera
7.3.3.3 Collaboration with AstraZeneca
7.4 Agilent Technologies (Dako)
7.4.1 Life Sciences and Diagnostics Business
7.4.2 Agilent Life Sciences and Diagnostics, Sales and Recent Performance Analysis, 2015
7.4.3 Agilent: Next Generation Sequencing Platforms
7.4.4 Recent Companion Diagnostic Collaborations
7.4.4.1 Agilent/ Merck: Several Cancer Collaborations
7.4.4.2 Agilent/Pfizer: An Ongoing Collaboration
7.4.4.3 Agilent/Bristol-Myers Squibb
7.5 Myriad Genetics
7.5.1 Acquisition of Myriad RBM: Increases the Company’s Market Share of Companion Diagnostics
7.5.2 Companion Diagnostic Service Offerings
7.5.3 Sales and Recent Performance Analysis, 2013-2014
7.5.3.1 myRisk: Next Generation Hereditary Cancer Testing
7.5.4 Myriad Genetics Recent Collaborations
7.5.4.1 Myriad/AstraZeneca: Premarket Approval Application
7.5.4.2 Acquisition of Crescendo Bioscience: Entry into the Autoimmune Market
7.5.4.3 Myriad/ TESARO Companion Collaboration
7.5.4.4 Collaboration with AbbVie
7.6 BioMérieux
7.6.1 Sales and Recent Performance Analysis, 2010-2015
7.6.2 Sales by Region, 2014
7.6.3 Sales by Technology, 2015
7.6.4 Companion Diagnostics: Recent M&A Activity & Collaboration
7.6.4.1 Collaboration with Gilead Sciences
7.6.4.2 Collaboration with Ipsen
7.6.4.3 Collaboration with Merck
7.6.4.4 Collaborations with GSK and Novartis
7.6.4.5 Mergers, Acquisitions and Collaborations
7.6.5 bioTheranostics: Subsidiary for Oncology Diagnostics
7.7 Thermo Fisher Scientific
7.7.1 Sales and Recent Performance Analysis, 2013-2014
7.7.1.1 Thermo Fisher Scientific Sales by Region, 2015
7.7.2 Recent Collaborations and Acquisitions
7.7.2.1 Acquisition of Life Technologies
7.7.2.2 Acquisition of Prionics
7.7.2.3 Acquisition of Advanced Scientifics, Inc.
7.7.2.4 Acquisition of Alfa Aesar
7.7.2.5 Affymetrix: Thermo Fisher’s Next Target
7.7.2.6 Thermo Fisher: Developing a ‘Universal’ Companion Diagnostics Using Next Generation Sequencing
7.7.2.7 Thermo Fisher: Life Technologies Collaborates with Merck Serono
7.7.2.8 Thermo Fisher Scientific Collaboration with Pfizer and Novartis to Offer NGS-Based Companion Test for NSCLC
8. Qualitative Analysis of the Companion Diagnostics Market, 2016-2026
8.1 SWOT Analysis of the Companion Diagnostics Market
8.2 Strengths
8.2.1 A CDx Strategy Decreases the Length of Approval Process
8.2.2 Premium Prices for Companion Diagnostics
8.2.3 A CDx Development Strategy Can Generate More Effective Drugs
8.2.4 Therapeutics Tied with CDx can have Safer Profiles
8.2.5 Reducing the Cost of Healthcare
8.2.6 Increased Regulatory Scrutiny on Marketed Drugs
8.2.7 Targeted Therapies Will Drive the CDx Market
8.3 Weaknesses
8.3.1 Reimbursement Challenges
8.3.2 Lack of Clear Regulatory Guidelines
8.3.3 Capital Intensity is High
8.4 Opportunities
8.4.1 Fast-growing Emerging Markets
8.4.2 Next Generation Sequencing
8.4.3 Many New CDx/ Pharma Company Partnerships
8.5 Threats
8.5.1 Complex Business Models and Business Partnerships
8.5.2 Medical Device Excise Tax
8.6 Porter’s Five Forces Analysis of the Companion Diagnostics Market
8.6.1 Rivalry Among Competitors [High]
8.6.2 Power of Suppliers [High]
8.6.3 Power of Buyers [Medium]
8.6.4 Threat of New Entrants [Medium]
8.6.5 Threat of Substitutes [High]
9. Conclusions
9.1 Overview
9.2 Theranostics: A Fast Growing Market
9.3 Leading Companion Diagnostic Companies
9.4 Pharmaceutical/Diagnostic Partnership Model
9.5 Oncology is the Leading Therapy Area Driving Companion Diagnostics
9.6 Commercial Drivers of the Companion Diagnostics Market
9.7 Commercial Restraints of the Companion Diagnostics Market
9.8 Concluding Remarks
10. Glossary
Appendix
Visiongain’s Bespoke Research Service
Some Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Report Evaluation Form
【レポート販売概要】
■ タイトル：コンパニオン診断（CDx）の世界市場予測2016-2026■ 英文：The Companion Diagnostics (CDx) Market Forecast 2016-2026
■ 発行日：2016年3月
■ 調査会社：visiongain
■ 商品コード：VGAIN6041538
■ 調査対象地域：グローバル
- ヨーロッパの小型商用車市場2016-2020About LCV In Europe, LCVs refer to commercial carrier vehicles of gross vehicle weights up to 3.5 tons. Gross vehicle weight refers to the operating weight, that is, the maximum weight a truck can carry while being driven. This includes the actual vehicle weight as well as passengers, cargo, and fuel weight. LCVs in Europe include pick-up trucks and vans that are used to carry a wide range of good …
- ろう付材料の世界市場：銀ろう、金ろうAbout Silver and Gold-based Brazing Materials Brazing is defined as the process of joining two metals by deploying a filler metal such as a brazing alloy. In the brazing process, the filler metal is heated slightly above its melting point and allowed to flow through capillary action in between the two base metals that require to be joined. This process is normally undertaken by using a controlled …
- ディスプレイの世界市場：従来型ディスプレイ、3Dディスプレイ、透過型ディスプレイ、フレキシブルディスプレイ、LED、OLED、LCD、電子ペーパーThe consumer electronics industry is witnessing an impressive increase in demandof displays in various consumer electronic devices. There has been a rapid expansion in the applications of displays in medical and automotive industries as well. The growth in advertising and publishing, military, and retail and banking segments is also one of the major drivers for the growth of global displays market …
- 術中神経モニタリング（IONM）の世界市場の規模と予測：タイプ別（インソースIONM、アウトソースIONM）、地域別（北アメリカ[米国、カナダ]、ヨーロッパ[英国、ドイツ]、アジア太平洋[日本、中国]、ラテンアメリカ[ブラジル、メキシコ]、MEA [南アフリカ]）、動向分析、2014-2025The global Intraoperative Neuromonitoring (IONM) market is expected to reach USD 3.6 billion by 2025, based on a new report by Grand View Research, Inc. The intraoperative neuromonitoring market is anticipated to witness significant growth in the forecast period, which can be attributed to the hospitals adopting intraoperative monitoring in a wide spectrum of surgeries. Major surgeries pose a risk …
- 原子力発電の新興国市場：予測、主要企業、開発分析Emerging Nuclear Power Countries - Market Forecast, Key Companies and Development Analysis to 2030 Summary The latest report from GlobalData, “Emerging Nuclear Power Countries - Market Forecast, Key Companies and Development Analysis to 2030” covers the emerging nuclear market and the key factors affecting demand. It also provides comprehensive information on key market players and their global ma …
- 3D度量衡学の世界市場：CMM（座標測定機）、VMM（ビデオ測定機）、ODS（光デジタイザ＆スキャナ）The 3D metrology market is expected to reach USD 10.90 Billion by 2022, at a CAGR of 7.0% between 2016 and 2022. The major factors driving the market are highly accurate inspection owing to three-dimensional data for modeling and analysis, increasing focus on quality control, and limitations of traditional measurement devices to address manufacturing issues. The market for the architecture and con …
- Cequence Energy Ltd.：石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Cequence Energy Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Cequence Energy Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source f …
- 世界のCAE（Computer-aided Engineering）市場動向（2012-2016）Introduction to the market Computer-aided engineering (CAE) is the practice of using a broad range of software products to assist in engineering tasks. These software products support a wide range of tasks such as the simulation, validation, analysis, and manufacture of engineering products. CAE includes two major tools-finite element analysis (FEA) and computational fluid dynamics (CFD). FEA is a …
- 欧州のリーフスプリング（板ばね）市場動向・予測The European leaf spring market is estimated to grow at a CAGR of 3.63% from 2016 to 2021. A leaf spring is a type of vehicle suspension system that is composed of numerous strips of steel orcomposite material joined together to work as a single unit. The strips are curved into an arc and attached to the frame. Leaf springs divide the vehicle weight evenly over the vehicle chassis to enhance the r …
- 半導体IPの世界市場：プロセッサIP、フィジカルIP、デジタルIPAbout Semiconductor IP Semiconductor IP is an integral part of electronic design and automation (EDA) process and are meant to aid design engineers and developers to develop new chips. The use of semiconductor IP blocks in lieu of the miniaturization of electronic products reduces the overall production cost. The growing complexity of semiconductor chip designs is adding to the importance of semic …
- 特権ID管理（PIM）の世界市場2016-2020About Privileged Identity Management PIM solutions protect, track, and audit privileged credentials used by IT administrators and applications when accessing sensitive information, including IP rights, company financials, and employee details. PIM is the highest priority for enterprise security because chief information officers, chief information security officers, and security managers are able …
- 薫製魚の世界市場2018-2022133 Pages, November 2018 About this market The rising popularity of online shopping is identified as one of the key trends that will gain traction in the market. It is encouraging various manufacturers to explore the online retail format and concentrate on the internet-savvy consumer segment. Operating costs and overheads for vendors are lower in the online retail format in comparison to the physi …
- 2014 Assessments of Leading Hemostasis Market Players–Strategic Analyses of Major Suppliers and Emerging Market EntrantsThis new report from Venture Planning Group provides strategic assessments of major suppliers of hemostasis diagnostic products, as well as emerging market entrants. The report presents analyses of major current and emerging suppliers of hemostasis instruments ans reagents, including:Sales estimatesMarket sharesProduct portfoliosMarketing tacticsTechnological know-howNew products in R&DCollabo …
- 世界の水力発電市場動向2013Update：市場規模、競争環境、規制、投資動向Hydropower (Large Hydro, Small Hydro and Pumped Storage), 2013 Update - Global Market Size, Competitive Landscape, Regulations and Investment Analysis to 2020 Summary “Hydropower (Large Hydro, Small Hydro and Pumped Storage), 2013 Update - Global Market Size, Competitive Landscape, Regulations and Investment Analysis to 2020” is the latest report from GlobalData, the industry analysis specialists …
- スマート教育の世界市場：コンテンツ、ソフトウェア、ハードウェアAbout Smart Education The education index of a country plays a crucial role in determining its economic competitiveness. Consequently, most governments are developing strategies to incorporate digital technology into the learning process. Education institutions are deploying hi-tech products to implement interactive learning methodologies. Proliferation of mobile devices such as tablets and smartp …
